Author： Phillips Kathryn A Veenstra David Bebber Stephanie Van Sakowski Julie
Publisher： Future Medicine
ISSN： 1462-2416
Source： Pharmacogenomics, Vol.4, Iss.3, 2003-05, pp. : 231-239
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
Cost–effectiveness analysis in pharmacogenomics
By Payne Katherine Shabaruddin Fatiha H
Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. :
Access to resources
Recommend
The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics
PharmacoEconomics, Vol. 22, Iss. 8, 2004-01 ,pp. :
Cost-Benefit Analysis of Amtolmetin-Guacil
Clinical Drug Investigation, Vol. 21, Iss. 1, 2001-01 ,pp. :
Estimating `Costs' for Cost-Effectiveness Analysis
By Miners Alec
PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. :